Overview

A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Status:
Completed

Trial end date:
2013-02-01

Target enrollment:

Participant gender:

Summary

Evaluate florbetapir (18F) positron emission tomography (PET) imaging for distinguishing Japanese healthy control subjects, from Japanese subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Avid Radiopharmaceuticals

Collaborator:

Eli Lilly and Company